Navigation Links
Dongsheng Pharmaceutical International Co. Granted Exclusive Sales Rights for Thymosin Alpha 1 Injection
Date:1/5/2011

NEW YORK, Jan. 5, 2011 /PRNewswire-Asia/ -- Dongsheng Pharmaceutical International Co., Ltd. (the "Company") (OTC Bulletin Board: DNGH) announced today that it has obtained the exclusive sales rights of Thymosin Alpha 1 Injection in 19 provinces in China from Shanghai Biochemistry Pharmaceutical Co. I.

The State Food and Drug Administration of China (the "SFDA") approved the manufacturing permit of Thymosin Alpha 1 Injection for Shanghai Biochemistry Pharmaceutical Co. I on June 29, 2010. Immediately after such approval, Shanghai Biochemistry submitted the manufactured samples to the SFDA for quality check, which is a necessary step to receive final approval for mass manufacturing. We expect that the samples will pass the quality check in the next 3-6 months, at which time Thymosin Alpha 1 Injection will be granted final approval for mass manufacturing.

Thymosin Alpha 1 Injection is an immune modifier that has been proven to be effective in the treatment of chronic hepatitis B, acute severe hepatitis, adjuvant therapy for tumor and immuno compromised diseases. Thymosin Alpha 1 Injection has been admitted into the China National Basic Medicine Coverage List, thereby making it more affordable to consumers and potentially increasing its demand.  In June 2010, Dongsheng commenced a marketing campaign for Thymosin Alpha 1 Injection within its sales and distribution network, and the response so far from potential customers has been promising.

Mr. Zhu XiaoDong, CEO of Dongsheng Pharmaceutical International, stated that, "Thymosin Alpha 1 is a high value and high margin medicine.  Obtaining exclusive sales rights for this product in 19 provinces represents another milestone that Dongsheng Pharmaceutical has accomplished since it went public in March 2010."  

About Dongsheng Pharmaceutical International Co., Ltd.

Headquartered in Chengdu, Sichuan Province, China, Dongsheng Pharmaceutical International Co., Ltd. engages in pharmaceutical technology promotion, trading and warehousing of traditional Chinese medicine and bio-chemistry products.  The Company sells prescription and non-prescription drugs and provides new medicine research and development and drug registration services distributing to more than 30 provinces in China and throughout Southeast Asia.  

For more information, please visit: www.eappic.com

Forward-Looking Statements

Pursuant to The Private Securities Litigation Reform Act of 1995, the statements in this press release that relate to the Company's expectations with regard to the future impact on the Company's results from new products in development are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are subject to risks and uncertainties. Words such as "expects", "intends", "plans", "may", "could", "should", "anticipates", "likely", "believes" and words of similar import also identify forward-looking statements. Forward-looking statements are based on current facts and analyses and other information that are based on forecasts of future results, estimates of amounts not yet determined and assumptions of management. You are urged not to place undue reliance on the forward-looking statements, which speak only as of the date of this release since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. We assume no obligation to publicly update or revise any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release, even if new information becomes available in the future. Additional information on risks and other factors that may affect the business and financial results of Dongsheng Pharmaceutical International Co., Ltd. can be found in the filings of Dongsheng Pharmaceutical International Co., Ltd. with the U.S. Securities and Exchange Commission.

Company Contact:

Dongsheng Pharmaceutical International Co., Ltd.
Ph: 201-898-0688 (US), 8610-88580780 (CHINA)
Email: eappic@eappic.com




'/>"/>
SOURCE Dongsheng Pharmaceutical International Co., Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. MAP Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
2. Lexicon Pharmaceuticals to Present at the 29th Annual JPMorgan Healthcare Conference
3. Anadys Pharmaceuticals Initiates Phase IIb Study of ANA598 in HCV Patients
4. Optimer Pharmaceuticals Receives Orphan Drug Designation for Fidaxomicin for the Treatment of Pediatric Clostridium difficile Infection
5. ADVENTRX Pharmaceuticals to Present at the 4TH Annual OneMedForum Business Development and Investment Conference on January 11
6. Webcast Alert: Isis Pharmaceuticals Holds Webcast to Discuss Recent Advances in its Development Pipeline
7. Syndax Pharmaceuticals to Present at Biotech Showcase 2011
8. Amylin Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
9. Par Pharmaceutical Begins Shipment of Generic Rythmol SR®
10. Par Pharmaceutical Begins Shipment of Generic Lotrel®
11. New Second Edition of Pharmaceutical Patent Law Examines Critical Intersection of Patent Law and Food and Drug Law
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... , Dec. 2, 2016  LifeVac, the revolutionary ... included in the Emergency Response Training and Support Services ... excited to have LifeVac become part of the ERTSS ... Founder and CEO of LifeVac. "Having an established network ... and effectively will help leverage our efforts to spread ...
(Date:12/2/2016)... India , December 2, 2016 ... report "In Vitro Diagnostics/IVD Market by Product (Instruments, ... Hematology), Application (Diabetes, Oncology, Cardiology, Nephrology, Infectious Diseases) ... global market is valued at USD 60.22 Billion ... at a CAGR of 5.5% during the forecast ...
(Date:12/2/2016)... 2, 2016 In the first ever attempt ... those derived from C. sativa, the Hebrew University in ... Napoli Federico II , the Universita` del Piemonte Orientale ... critical, integrated and unified inventory of phytocannabinoids of different ... on the remarkable chemical and structural diversity of phytocannabinoids. ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... December 02, 2016 , ... Advanced Inc., a leading provider of ... Bice, CPA, MBA to serve as Advanced Inc.’s Chief Financial Officer, effective December 1, ... Jason brings extensive financial and operational leadership experience to Advanced Inc. He began his ...
(Date:12/2/2016)... ... December 02, 2016 , ... The annual time frame to change Medicare health ... is ending December 7th. Currently-enrolled Medicare beneficiaries who are looking to switch from their ... D) need to make changes during this period order for their new policy to ...
(Date:12/2/2016)... NY (PRWEB) , ... December 02, 2016 , ... ... an inspirational interview of two ostomy patients, standing as living proof that attitude ... suffer from digestive diseases and issues that spike around the holidays. This campaign ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... "Cardiovascular Health" in USA Today, which covers the innovative treatments, therapeutic technologies, and ... maintaining fulfilling lives. “We are prolonging life 6 years in the last 3 ...
(Date:12/2/2016)... ... 2016 , ... Universal Medical Systems, Inc. (UMS) the world's ... to offer robotic imaging to veterinary medicine is sponsoring the appearance of Millennia, ... American Association of Equine Practitioners 62nd Annual Convention from December 4-6, 2016 in ...
Breaking Medicine News(10 mins):